SEC Form 4 · accession 0000899243-18-025002
T2 Biosystems, Inc. · TTOO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas J. Lowery
Officer — Chief Scientific Officer
Period of report
Sep 20, 2018
Accepted (ET)
Sep 21, 2018 · 4:00 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001492674
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 20, 2018 | M | 31,603 | $3.22 | A | 74,829 | D | |
| Common Stock | Sep 20, 2018 | M | 16,602 | $3.22 | A | 91,431 | D | |
| Common StockF2 | Sep 20, 2018 | S | 48,205 | $6.18 | D | 43,226 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $3.22 | Sep 20, 2018 | M | 31,603 | D | Sep 25, 2017 | Sep 25, 2023 | Common Stock | 31,603 | 0 | D |
| Stock Option (Right to Buy) | $3.22 | Sep 20, 2018 | M | 16,602 | D | Jan 22, 2018 | Jan 22, 2024 | Common Stock | 16,602 | 0 | D |
Explanation of responses
- F1The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2018.
- F2The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $6.02 to $6.38. The reporting person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.